PhRMA Clinical Trial Code: Disclosure Edition
This article was originally published in The Pink Sheet Daily
Executive Summary
PhRMA is using broad disclosure as a defense against questions of clinical trial bias. Disclosure used to be a penalty forced on firms in consent decrees and lawsuits; now it appears as a pillar to building trust for corporate-sponsored trials.
You may also be interested in...
IFPMA Clinical Trials Disclosure Code Covers All Studies Of Life-Threatening Conditions
The International Federation of Pharmaceutical Manufacturers & Associations' Council on Nov. 10 expanded the group's clinical trials disclosure policy to cover all clinical trials, other than exploratory trials
Clinical Trials Disclosure Code From International Group Covers All Studies Of Life-Threatening Conditions
IFPMA says policy covers early stage safety trials -- a subset not mentioned in PhRMA's Clinical Trial Code.
Clinical Trials Disclosure Code From International Group Covers All Studies Of Life-Threatening Conditions
IFPMA says policy covers early stage safety trials -- a subset not mentioned in PhRMA's Clinical Trial Code.